{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:30Z","timestamp":1786119450330,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/md.0000000000003245","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T10:26:47Z","timestamp":1461061607000},"page":"e3245","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of Ivabradine in Treating Stable Angina Pectoris"],"prefix":"10.1097","volume":"95","author":[{"given":"Liwen","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhi","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-40-20210226","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00126839-200304020-00001","article-title":"Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology","volume":"4","author":"Camm","year":"2003","journal-title":"Drugs RD"},{"key":"R2-40-20210226","doi-asserted-by":"crossref","first-page":"H672","DOI":"10.1152\/ajpheart.00547.2001","article-title":"Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise","volume":"282","author":"Colin","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R3-40-20210226","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10557-011-6327-3","article-title":"Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina","volume":"25","author":"Amosova","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"R4-40-20210226","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Antianginal and antiischemic effects of ivabradine, an I (f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"R5-40-20210226","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J"},{"key":"R6-40-20210226","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/pds.3628","article-title":"The efficacy and safety of ivabradine hydrochloride versus atenolol in Chinese patients with chronic stable angina pectoris","volume":"23","author":"Li","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R7-40-20210226","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective I (f) inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J"},{"key":"R8-40-20210226","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I (f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"key":"R9-40-20210226","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ijcard.2012.10.011","article-title":"Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study","volume":"168","author":"Tardif","year":"2013","journal-title":"Int J Cardiol"},{"key":"R10-40-20210226","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R11-40-20210226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R12-40-20210226","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"R13-40-20210226","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"R14-40-20210226","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(06)68770-9","article-title":"Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data","volume":"367","author":"Lopez","year":"2006","journal-title":"Lancet"},{"key":"R15-40-20210226","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1056\/NEJM199604043341403","article-title":"Recent trends in acute coronary heart disease\u2013mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators","volume":"334","author":"McGovern","year":"1996","journal-title":"N Engl J Med"},{"key":"R16-40-20210226","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1503\/cmaj.150535","article-title":"Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis","volume":"188","author":"Zhang","year":"2016","journal-title":"CMAJ"},{"key":"R17-40-20210226","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","article-title":"Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in cibisii trial","volume":"103","author":"Lechat","year":"2001","journal-title":"Circulation"},{"key":"R18-40-20210226","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"R19-40-20210226","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"},{"key":"R20-40-20210226","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"R21-40-20210226","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2048872613489305","article-title":"Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study","volume":"2","author":"Steg","year":"2013","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R22-40-20210226","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/eurheartj\/eht101","article-title":"Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials","volume":"34","author":"Fox","year":"2013","journal-title":"Eur Heart J"},{"key":"R23-40-20210226","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000108387","article-title":"Long-term safety and efficacy of ivabradine in patients with chronic stable angina","volume":"108","author":"Lorenzo L\u00f3pez-Besc\u00f3s","year":"2007","journal-title":"Cardiology"},{"key":"R24-40-20210226","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000380812","article-title":"Effect of combining ivabradine and (-blockers: focus on the use of carvedilol in the SHIFT population","volume":"131","author":"Bocchi","year":"2015","journal-title":"Cardiology"},{"key":"R25-40-20210226","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"},{"key":"R26-40-20210226","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MJT.0b013e3182246a49","article-title":"Reduction of resting heart rate with antianginal drugs: review and meta-analysis","volume":"19","author":"Cucherat","year":"2012","journal-title":"Am J Ther"},{"key":"R27-40-20210226","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis","volume":"22","author":"Belsey","year":"2015","journal-title":"Eur J Prev Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000003245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:16Z","timestamp":1786039876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201604050-00040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003245","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}